Dr. David Maag, PhD

Executive Director, Clinical Development at Intellia Therapeutics

Speaker

David Maag leads the clinical development program for NTLA-2002, Intellia’s investigational in vivo CRISPR/Cas9 gene editing therapy for the treatment of hereditary angioedema. Since joining Intellia in 2021, he has led this program from the first-in-human trial through the ongoing pivotal phase 3 HAELO trial, which is now enrolling globally. David has 15 years of industry experience spanning drug discovery through late-stage clinical development, including small molecules, biologics, and ATMPs. He obtained his B.S. in Biochemistry from the Pennsylvania State University and his Ph.D. in Biophysics and Biophysical Chemistry from the Johns Hopkins University School of Medicine.